Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
0.895
+0.001 (0.10%)
Jun 21, 2024, 2:05 PM EDT - Market open

Lineage Cell Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 1996
Cash & Equivalents
35.4411.3655.7432.599.5
Upgrade
Short-Term Investments
0.0546.522.628.9844.84
Upgrade
Cash & Cash Equivalents
35.4957.8858.3641.5654.33
Upgrade
Cash Growth
-38.67%-0.83%40.41%-23.50%76.74%
Upgrade
Receivables
0.750.350.8400.32
Upgrade
Other Current Assets
2.21.832.352.432.86
Upgrade
Total Current Assets
38.4460111.554457.52
Upgrade
Property, Plant & Equipment
4.775.674.875.638.18
Upgrade
Goodwill and Intangibles
57.2357.3657.4957.758.92
Upgrade
Other Long-Term Assets
0.580.630.630.620.86
Upgrade
Total Long-Term Assets
62.5863.666363.9567.96
Upgrade
Total Assets
101.02123.66174.55107.95125.48
Upgrade
Accounts Payable
6.278.6127.976.815.23
Upgrade
Deferred Revenue
29.537.1550.570.190.25
Upgrade
Current Debt
0.880.950.830.761.22
Upgrade
Other Current Liabilities
-18.69-27.73-32.260-0.2
Upgrade
Total Current Liabilities
17.9618.9847.127.776.49
Upgrade
Long-Term Debt
2.072.941.972.543.95
Upgrade
Other Long-Term Liabilities
18.9729.834.562.513.79
Upgrade
Total Long-Term Liabilities
21.0432.7536.535.057.74
Upgrade
Total Liabilities
3951.7383.6512.8214.23
Upgrade
Total Debt
2.953.92.83.35.17
Upgrade
Debt Growth
-24.23%39.04%-15.14%-36.11%128.17%
Upgrade
Retained Earnings
-384.86-363.37-337.1-294.08-273.42
Upgrade
Comprehensive Income
-3.07-3.57-5.21-3.67-0.68
Upgrade
Shareholders' Equity
63.4273.3492.2296.2112.96
Upgrade
Net Cash / Debt
32.5453.9855.5638.2649.16
Upgrade
Net Cash / Debt Growth
-39.72%-2.84%45.21%-22.18%72.65%
Upgrade
Net Cash Per Share
0.190.320.340.250.34
Upgrade
Working Capital
20.4841.0264.4336.2351.03
Upgrade
Book Value Per Share
0.370.430.560.640.78
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).